ANE 2023 Poster C010

A Comprehensive Predictive Biomarker Analysis for MEK Inhibitor, Trametinib, in Patient-Derived Xenograft (PDX) Models

Yanghui Sheng , Wubin Qian , Jessie Wang , Sheng Guo

Crown Bioscience Inc., 218 Xinghu Street, Suzhou, Jiangsu, 215000, China

The RAS-RAF-MEK-ERK pathway is a focal point in cancer research. As MEK inhibition emerges as a promising treatment, the quest to find reliable biomarkers predicting efficacy intensifies. Our study navigates through PDX models, bridging in vitro and in vivo insights about trametinib's potential.

Download this Poster to Discover:

• The significance of the RAS-RAF-MEK-ERK pathway in cancer progression.
  
  
• Advanced methodologies using PDX models to spotlight trametinib efficacy biomarkers.
  
  
• Revelations on both validated and novel biomarkers shaping cancer therapy's future.

Download the Poster Now!